Molecular Partners Ag (MOLN) Accounts Payables (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Accounts Payables of $2458.2 for Q1 2026, down 7.76% year-over-year from $2665.0 in Q1 2025, and up 11.19% quarter-over-quarter from $2210.8 in Q4 2025.
Molecular Partners Ag (MOLN) Accounts Payables (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Accounts Payables for 7 consecutive years, with $2458.2 the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables fell 7.76% year-over-year to $2458.2; the TTM figure through Mar 2026 stood at $2458.2 (down 7.76% YoY), while the FY2025 annual figure was $2210.8, down 99.9% from the prior year.
- Accounts Payables rose to $2458.2 in Q1 2026 per MOLN's latest filing, from $2210.8 in the prior quarter.
- Across five years, Accounts Payables topped out at $5.8 million in Q2 2022 and bottomed at $2210.8 in Q4 2025.
- Historically, Accounts Payables has averaged $1.0 million across 5 years, with a median of $3539.2 in 2022.
- Annual changes were most pronounced in 2024 — Accounts Payables jumped 41.74% — and 2025, when it tumbled 99.92%.
- Molecular Partners Ag's Accounts Payables stood at $2.2 million in 2022, then plunged by 32.7% to $1.5 million in 2023, then jumped by 41.74% to $2.1 million in 2024, then tumbled by 99.9% to $2210.8 in 2025, then grew by 11.19% to $2458.2 in 2026.
- Business Quant data shows MOLN's Accounts Payables at $2458.2 in Q1 2026, $2210.8 in Q4 2025, and $2654.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - | 2,458.23 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2,458.23 |
| Dec 31, 2025 | 2,210.82 |
| Sep 30, 2025 | 2,653.98 |
| Jun 30, 2025 | 2,380.75 |
| Mar 31, 2025 | 2,664.95 |
| Dec 31, 2024 | 2.12 Mn |
| Sep 30, 2024 | 2,749.32 |
| Jun 30, 2024 | 3.16 Mn |
| Mar 31, 2024 | 3,676.49 |
| Dec 31, 2023 | 1.50 Mn |
| Sep 30, 2023 | 2,380.92 |
| Jun 30, 2023 | 3.05 Mn |
| Mar 31, 2023 | 3,091.04 |
| Dec 31, 2022 | 2.22 Mn |
| Sep 30, 2022 | 3,539.19 |
| Jun 30, 2022 | 5.76 Mn |
| Mar 31, 2022 | 4,926.78 |
| Dec 31, 2021 | 8.01 Mn |
| Sep 30, 2021 | 4,136.51 |
| Dec 31, 2020 | 6.44 Mn |